Search results
Novartis AG (NYSE:NVS) Shares Sold by Cannell & Co.
ETF DAILY NEWS· 1 week agoCannell & Co. trimmed its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 19.2% in the 4th quarter, according to the company in its most recent 13F filing with ...
Novartis to Buy Mariana Oncology, Paying $1 Billion Upfront
Bloomberg· 1 week agoNovartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can...
Why selling to Novartis made sense for Mariana
BioPharma Dive via Yahoo Finance· 1 week ago“The inbound interest was broad and almost frenetic,” said company CEO Simon Read in an interview...One of those conversations led to Mariana’s own deal,...
Novartis further entrenches into radiopharma with $1B Mariana buy
FierceBiotech· 1 week agoWith much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep...
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoThe Irish government and its foreign direct investments agency IDA Ireland are increasingly...
Novartis pays PeptiDream $180M as radiopharma big bang continues
FierceBiotech· 2 weeks agoJapan’s PeptiDream began working with Novartis in 2010 and, after repeatedly adding to the original deal, formed a collaboration focused on PDCs in 2019 ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 week agoIn this feature, we analyse publicly available data on how much leading pharma companies have spent on R&D...Merck & Co- $30.5bn Roche- $15.56bn (CHF...
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
BioPharma Dive via Yahoo Finance· 1 week agoYet they’re difficult to manufacture, as they pair a radioactive isotope like lutetium or actinium...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 2 weeks agoSource: Global Cancer Observatory. Analysts forecast Novartis' second-quarter earnings per share to be between $1.78 and $1.84, remaining almost...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 2 weeks agoIt also notified the FDA that it disputes the patent listings. The letters targeted what agency...
